CN106536489B - 类视黄醇相关孤儿受体γ调节剂及其用途 - Google Patents

类视黄醇相关孤儿受体γ调节剂及其用途 Download PDF

Info

Publication number
CN106536489B
CN106536489B CN201580039564.9A CN201580039564A CN106536489B CN 106536489 B CN106536489 B CN 106536489B CN 201580039564 A CN201580039564 A CN 201580039564A CN 106536489 B CN106536489 B CN 106536489B
Authority
CN
China
Prior art keywords
methyl
methylpiperazin
chloro
methylphenyl
cyclopentylcarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580039564.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN106536489A (zh
Inventor
邓菁
雷晖
马欣
林熹晨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CN106536489A publication Critical patent/CN106536489A/zh
Application granted granted Critical
Publication of CN106536489B publication Critical patent/CN106536489B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN201580039564.9A 2014-05-28 2015-05-26 类视黄醇相关孤儿受体γ调节剂及其用途 Active CN106536489B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/000540 2014-05-28
CN2014000540 2014-05-28
PCT/CN2015/079753 WO2015180612A1 (en) 2014-05-28 2015-05-26 Novel compounds

Publications (2)

Publication Number Publication Date
CN106536489A CN106536489A (zh) 2017-03-22
CN106536489B true CN106536489B (zh) 2020-02-07

Family

ID=54698093

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580039564.9A Active CN106536489B (zh) 2014-05-28 2015-05-26 类视黄醇相关孤儿受体γ调节剂及其用途

Country Status (12)

Country Link
US (1) US9902735B2 (https=)
EP (1) EP3148975B1 (https=)
JP (1) JP6759110B2 (https=)
KR (1) KR20170012389A (https=)
CN (1) CN106536489B (https=)
AU (1) AU2015267909B2 (https=)
BR (1) BR112016027732B1 (https=)
CA (1) CA2950211C (https=)
ES (1) ES2710487T3 (https=)
MX (1) MX378098B (https=)
RU (1) RU2016150535A (https=)
WO (1) WO2015180612A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014086894A1 (en) 2012-12-06 2014-06-12 Glaxo Group Limited Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
WO2015180613A1 (en) 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds
JP6522665B2 (ja) 2014-05-28 2019-05-29 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規化合物
EP3474942B1 (en) * 2016-06-23 2023-07-19 Kessler Foundation Inc. Testosterone replacement therapy in combination with neuromuscular stimulation
CN109476653B (zh) * 2016-07-13 2022-04-22 利奥制药有限公司 类视黄醇相关孤儿受体γ的杂芳族调节剂
AU2017379024B2 (en) 2016-12-21 2021-03-04 Jiangsu Hengrui Medicine Co., Ltd. Condensed ring group azacyclobutyl triazole derivative, preparation method therefor and use thereof in medicine
CA3047641A1 (en) 2016-12-28 2018-07-05 Jiangsu Hengrui Medicine Co., Ltd. Azabicyclo-substituted triazole derivative, preparation method thereof, and application of same in medicine
CN109134476B (zh) * 2017-06-15 2021-03-19 复旦大学 桥环哌嗪类衍生物或其盐及其制备方法和用途
TW201910312A (zh) * 2017-07-28 2019-03-16 日商東麗股份有限公司 環狀胺衍生物及其醫藥用途
CN107698462A (zh) * 2017-10-10 2018-02-16 重庆科脉生物化工有限公司 一种1‑氨基‑1‑环丙腈盐酸盐的制备方法
CN109438423A (zh) * 2018-09-12 2019-03-08 通化师范学院 一种肺癌靶向化合物azd-3759的合成工艺的新方法
WO2021177431A1 (ja) * 2020-03-06 2021-09-10 日産化学株式会社 新規触媒組成物並びに窒素含有基を有する炭素材料
AU2021287462A1 (en) * 2020-06-09 2023-02-09 Relive Therapeutics Inc. Compounds comprising a three ring core as PD-1/PD-L1 blockers
CN116239445B (zh) * 2023-01-05 2024-10-18 万华化学集团股份有限公司 一种丙内酯开环加氢合成1,3-丙二醇的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022257A2 (en) * 2005-08-16 2007-02-22 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
WO2012027965A1 (en) * 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012139775A1 (en) * 2011-04-14 2012-10-18 Phenex Pharmaceuticals Ag Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor rar-related orphan receptor-gamma (rorgamma, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2012158784A2 (en) * 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022597A1 (en) * 1995-12-18 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives as tachykinin antagonists
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
EP1962852B1 (en) 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
WO2012145254A2 (en) 2011-04-16 2012-10-26 Board Of Regents, The University Of Texas System Methods of using inhibitors of rorϒt to treat disease
WO2012147916A1 (ja) 2011-04-28 2012-11-01 日本たばこ産業株式会社 アミド化合物およびその医薬用途
BR112014005268A2 (pt) 2011-09-09 2017-03-28 Univ New York compostos de amido como moduladores de ror t e usos dos mesmos
GB201116641D0 (en) 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
GB201207406D0 (en) 2012-04-27 2012-06-13 Glaxo Group Ltd Novel compounds
CA2871534A1 (en) 2012-04-27 2013-10-31 Glaxo Group Limited Novel compounds
WO2014086894A1 (en) * 2012-12-06 2014-06-12 Glaxo Group Limited Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
US10286000B2 (en) 2013-10-25 2019-05-14 St. Jude Children's Research Hospital, Inc. Retinoid X receptor-gamma agonists and retinoid X receptor-alpha antagonists for treatment of cancer
MX2016005348A (es) 2013-10-25 2016-08-11 Glaxosmithkline Llc Compuestos novedosos.
JP6522665B2 (ja) 2014-05-28 2019-05-29 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規化合物
WO2015180613A1 (en) 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022257A2 (en) * 2005-08-16 2007-02-22 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
WO2012027965A1 (en) * 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012139775A1 (en) * 2011-04-14 2012-10-18 Phenex Pharmaceuticals Ag Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor rar-related orphan receptor-gamma (rorgamma, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2012158784A2 (en) * 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror

Also Published As

Publication number Publication date
CN106536489A (zh) 2017-03-22
WO2015180612A1 (en) 2015-12-03
JP2017516796A (ja) 2017-06-22
BR112016027732A2 (https=) 2017-08-15
AU2015267909A1 (en) 2016-12-01
CA2950211A1 (en) 2015-12-03
BR112016027732B1 (pt) 2023-11-07
RU2016150535A3 (https=) 2018-12-26
EP3148975B1 (en) 2018-11-28
KR20170012389A (ko) 2017-02-02
CA2950211C (en) 2023-02-07
RU2016150535A (ru) 2018-07-03
US9902735B2 (en) 2018-02-27
JP6759110B2 (ja) 2020-09-23
US20170197978A1 (en) 2017-07-13
EP3148975A1 (en) 2017-04-05
EP3148975A4 (en) 2018-01-03
AU2015267909B2 (en) 2018-03-22
MX378098B (es) 2025-03-10
MX2016015630A (es) 2017-04-25
ES2710487T3 (es) 2019-04-25

Similar Documents

Publication Publication Date Title
CN106536489B (zh) 类视黄醇相关孤儿受体γ调节剂及其用途
EP3728238B1 (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
EP3468960B1 (en) Chemical compounds as atf4 pathway inhibitors
JP6279605B2 (ja) 自己免疫疾患および炎症性疾患の処置に使用するためのレチノイド関連オーファン受容体ガンマ（ＲＯＲγ）のモジュレーター
WO2019025467A1 (en) SELECTIVE INHIBITORS OF INFLAMMASOME NLRP3
JP7612663B2 (ja) （２－アセタミジル）チオ－ベータ－ｄ－ガラクトピラノシド誘導体
JP2022546029A (ja) アルファ－ｄ－ガラクトピラノシド誘導体
CN107001342B (zh) 新化合物
JP2017521426A (ja) Ｎａｍｐｔ抑制物質としての４，５−ジヒドロイソオキサゾール誘導体
EA030116B1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
JP2017516800A (ja) 新規な化合物
KR20180070697A (ko) Ror감마t 저해제로서의 치환된 인다졸 화합물 및 이의 용도
JP2024512874A (ja) キノキサリン誘導体及びその使用
EP4214210B1 (en) Compounds and compositions as sppl2a inhibitors
US20250206745A1 (en) Pyrrolopyridazine derivatives and related uses
HK40039990B (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
HK40039990A (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
HK40008443A (en) Imidazopyrrolopyridine as inhibitors of the jak family of kinases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant